Feb. 12, 2025 — Cortechs.ai, a supplier of novel imaging solutions for prostate cancer care, and EDAP TMS SA, a provider of robotic energy-based therapies, have announced the successful completion of the world’s first OnQ Prostate-assisted Focal One Robotic HIFU procedure at the University of California, San Francisco (UCSF) Prostate Center. This marks the first clinical application of OnQ Prostate’s patented RSI technology to guide focal therapy, demonstrating how advanced MR-imaging can improve lesion localization and targeting for urologists performing focal therapy.

Feb. 11, 2025 – Harrison.ai, a developer of AI-powered medical diagnostic support and workflow solutions, has announced the accelerated expansion of its operations into the United States — a move supported by US$112 million of Series C funding. The funding will also fuel the company’s product roadmap and continued growth in the UK, EMEA and APAC. 

Feb. 10, 2025 —Ibex Medical Analytics recently announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for Ibex Prostate Detect, an in vitro diagnostic medical device that harnesses AI to generate heatmaps identifying small and rare missed prostatic cancers, acting as a safety net to assist pathologists in ensuring patients receive an accurate diagnosis. 

Feb. 5, 2025 — According to research published in the American Journal of Roentgenology (AJR), photon-counting detector CT (PCD CT) yielded meaningful attenuation increases for gadoxetate disodium at considerably lower doses than previously documented for CT of gadolinium-based contrast agents (GBCAs) —albeit too high for clinical use (approximately 8-times greater than clinical doses).

Feb. 5, 2025 — Results of a new randomized trial involving more than 105,000 women reveals that the use of artificial intelligence (AI) in mammography screening significantly increases cancer detection rates while reducing the workload for radiologists.

Feb. 5, 2025 — Serac Healthcare Ltd., a clinical radiopharmaceutical company developing an innovative molecular imaging agent, said it has received positive feedback from its End of Phase II Meeting with the US Food and Drug Administration (FDA) for the development of 99mTc-maraciclatide as a diagnostic agent for use with single-photon emission computed tomography (SPECT-CT) for the visualization and diagnosis of superficial peritoneal endometriosis (SPE) in women aged 16 years of age and older.

Feb. 4, 2025 — Riverain Technologies recently announced it expanded across eight countries in 2024 and added nearly 50 new customers with its ClearRead solutions to clearly, confidently and quickly detect cardiothoracic diseases.

Feb. 3, 2025 — Lunit, a provider of AI-powered solutions for cancer diagnostics and therapeutics, has entered into a partnership with the Society for Immunotherapy of Cancer (SITC). This collaboration will launch the "Lunit Research Program" for SITC members, granting access to Lunit SCOPE IO for quantitative immune phenotyping and tumor microenvironment (TME) analysis from H&E whole slide images (WSIs).

Feb. 3, 2025 — RapidAI has received FDA 510(k) clearance for Lumina 3D by RapidAI — an automated 3D imaging reconstruction solution designed to replace manual workflows with an AI-powered approach based on the latest groundbreaking AI technology advances.

eHealth Saskatchewan plays a vital role in providing IT services to patients, health care providers, and partners such as the Ministry of Health and the Saskatchewan Health Authority in Canada. 

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now